Presbia PLC (NasdaqGM:LENS) intend to use the net proceeds from this rights offering for general corporate purposes, including funding our U.S. staged pivotal trial for our microlens and microlens inserter. We will also fund our commercialization efforts, research and development activities, product manufacturing, acquisitions or investments in businesses, products or technologies that are complementary to our own. See “Use of Proceeds.”